Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/RXK3 stock hub

FRA/RXK3 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/RXK3is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

785.5M

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/RXK3FRA/RXK3

—

Loading chart…

In the news

Latest news · FRA/RXK3

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-66.9

P25 n/aP50 n/aP75 n/a

ROIC-41.3

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/RXK3 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

130

Groups with data

Currency

USD

Showing 130 of 130 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	13
Employees Change	-2%
Employees Change Percent	-13.33
Enterprise value	EUR 725.3M
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 785.5M
Price	EUR 4.13
Price currency	EUR
Sic	2836
Symbol	fra/RXK3
Website	https://sellaslifesciences.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-2.91%
EV Earnings	-31.7x
P/B ratio	13.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	EUR -22.9M
Profit Per Employee	EUR -1.8M
ROA	-34.74
Roa5y	-96.21
ROCE	-38.1
ROE	-66.88
ROIC	-41.25

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	178.5%
Cagr3y	42.8%
Cagr5y	-8.43%

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	EUR 66.7M
Cash	EUR 61.1M
Current Assets	EUR 63.8M
Current Liabilities	EUR 6M
Debt	EUR 852,552
Debt Equity	EUR 0.01
Equity	EUR 60.4M
Liabilities	EUR 6.4M
Long Term Assets	EUR 3M
Long Term Liabilities	EUR 415,457
Net Cash	EUR 60.3M
Net Cash By Market Cap	EUR 7.68
Net Cash Growth	449.41%
Net Debt Equity	EUR -1
Tangible Book Value	EUR 58.7M
Tangible Book Value Per Share	EUR 0.38

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	10.72
Net Working Capital	EUR -2.6M
Quick ratio	10.23
Working Capital	EUR 58.1M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-78.18%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	178.3%
200-day SMA	2.57
3Y total return	191.26%
50-day SMA	4.23
50-day SMA vs 200-day SMA	50over200
5Y total return	-35.62%
All Time High	435
All Time High Change	-99.05%
All Time High Date	2018-04-03
All Time Low	0.45
All Time Low Change	817.78%
All Time Low Date	2024-01-12
ATR	0.18
Ch YTD	47.5
High	4.13
High52	5.36
High52 Date	2026-03-10
High52ch	-22.95%
Low	4.13
Low52	1.2
Low52 Date	2025-11-18
Low52ch	243.59%
Ma50ch	-2.36%
Price vs 200-day SMA	60.89%
RSI	50.28
RSI Monthly	60.44
RSI Weekly	61.58
Sharpe ratio	1.53x
Sortino ratio	2.76
Total Return	-78.18%
Tr YTD	47.5
Tr1m	5.63%
Tr1w	0.73%
Tr3m	29.67%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR -23.1M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	183,735,143%
Shares Insiders	0.43%
Shares Institutions	22.84%
Shares Qo Q	30.32%
Shares Yo Y	78.18%
Short Ratio	9.3

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	1,200.5x
Bv Per Share	0.39
Ch1m	5.63
Ch1w	0.73
Ch1y	178.3
Ch3m	29.67
Ch3y	191.3
Ch5y	-35.62
Ch6m	197.6
Change	-4.62%
Change From Open	0
Close	4.33
Days Gap	-4.62
Earnings Date	2026-05-11
EBIT	EUR -23.1M
EPS	EUR -0.21
F Score	1
Financing CF	73,498,303
Fiscal Year End	December
Goodwill	1,622,999.3
Is Primary Listing	0
Last Report Date	2025-12-31
Last Split Date	2019-11-08
Last Split Type	Reverse
Ma150	2.94
Ma150ch	40.72%
Ma20	4.12
Ma20ch	0.17%
Net CF	49,319,392
Next Earnings Date	2026-05-11
Open	4.13
Ppne	816,587.4
Price Date	2026-05-08
Ptbv Ratio	13.37
Relative Volume	0.42x
Share Based Comp	1,665,925
Tr6m	197.55%
Volume	0

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/RXK3 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/RXK3 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/RXK3?

Insider, institutional, and short-interest positioning.

Institutional ownership

+22.8%

Share of float held by funds and institutions

Insider ownership

+0.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

FRA/RXK3 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

50.3

Neutral momentum band

Price vs 200-day MA

+60.9%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

1.53

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/RXK3

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/RXK3 stock rating?

fra/RXK3 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/RXK3 analysis?

The full report lives at /stocks/fra/RXK3/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/RXK3?

The latest report frames fra/RXK3 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/RXK3 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.